Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Docetaxel, Estramustine, and Thalidomide in Patients With Hormone-Refractory Prostate Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Completed	Over 18	Other	NH-0139 NCI-V01-1681, NCT00046826

Trial Description

Purpose:

Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with thalidomide may kill more tumor cells.

Phase II trial to study the effectiveness of combining docetaxel and estramustine with thalidomide in treating patients who have prostate cancer previously treated with hormone therapy.

Eligibility:

Eligibility criteria include the following:

• At least 19 years old
• No CNS metastases
• No previous chemotherapy for prostate cancer
• At least 4 weeks since hormone therapy or radiation therapy
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive estramustine by mouth for 3 days and a 1-hour infusion of docetaxel on day 2. This treatment will continue for 3 weeks. Treatment may be repeated every 4 weeks for at least six courses. Patients will also receive thalidomide by mouth once a day for up to 1 year. Patients will be evaluated once a month.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Whittingham Cancer Center at Norwalk Hospital

Richard Frank, MD, Protocol chair		Ph: 203-845-2132

Registry Information
Official Title		A Phase II Clinical Trial of Taxotere, Emcyt and Thalidomide (TET) for the Treatment of Hormone-Refractory Prostate Cancer
Trial Start Date		2001-09-20
Trial Completion Date		2007-06-07
Registered in ClinicalTrials.gov		NCT00046826
Date Submitted to PDQ		2001-10-17
Information Last Verified		2006-01-13

Back to Top